I’m a bit puzzled why none of this was included in monthly progress reports from March 2020, as decisions were being made. That is what I had assumed would happen. That way, we could have scrutinised these decisions and processes before people were appointed.
When we heard nothing for 14+ months I assumed that work had stalled. Instead, it appears that a great deal of work was going on but for some reason we weren’t being told about it. Please can you clarify why that was, Hilda?
Since I joined this Forum in May, I assured people that we were working hard and making progress: because reporting was delayed didn't mean that progress and involvement of people with ME/CFS wasn't happening. The March report stated explicitly that we were engaged in establishing an IAG and author team, an address for questions was provided, and questions were answered. And I was answering questions here on this Forum, too.
After the report of 20 March 2020, the pandemic hit its stride, slowing people down generally, and pretty much everything that wasn't pandemic response. For me, trying to ensure that all this didn't end up with the review taking months longer - and those pandemic months turned into a lot of months - meant prioritizing doing what was needed to try to avoid large time over-runs. Without the enormous upheaval of a pandemic, it would have gone differently: this was a very bad time to be trying to undertake something like this. Unfortunately, that's the short straw this process drew.
The time that goes into development and feedback rounds of a substantive report, and setting aside time to respond to questions and feedback about that report when released, was a priority. However, the work on the engagement with the existing critiques and feedback, was a higher one - for the actual review work, but also as it is critical to the consultation process we will be starting. It would have been better to at least formalize as brief updates what I was communicating here and on Twitter.
It was clear the process used to establish these teams, and their members, would be criticized. Issuing a substantive report on the teams was going to require time to respond after that, and I considered allowing that time part of the task, not just its development and discussions about drafts.
Issuing brief reports that we were progressing with what we reported on in March 2020 wouldn't have satisfied what I'm hearing here: if I'm understanding correctly, that seems to be wanting to ensure there was a process more similar, for example, to that undertaken for clinical guideline committees at some major public agencies. Various recruitment options will be discussed by the IAG and in Cochrane as part of considerations and recommendations at the end of the process.